Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

6/4/21 6:09:49 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$WINT

Date	Price Target	Rating	Analyst